Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31:1154–62.
Google Scholar
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
Google Scholar
Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. 2022;17:181–204.
Google Scholar
Wei R, Liu S, Zhang S, Min L, Zhu S. Cellular and extracellular components in tumor microenvironment and their application in early diagnosis of cancers. Anal Cell Pathol. 2020;2020:6283796.
Google Scholar
Gysler SM, Drapkin R. Tumor innervation: peripheral nerves take control of the tumor microenvironment. J Clin Investig. 2021;131:e147276.
Wang X, Fan Y, Wang Q, Shu X, Lin J, Guo J, et al. Tumor-infiltrating nerves: unraveling the role of cancer neuroscience in tumorigenesis, disease progression, and emerging therapies. Discov Oncol. 2025;16:1209.
Google Scholar
Sloan EK. Harnessing brain-body communication to understand cancer. Genes Dev. 2024;38:820–2.
Google Scholar
Restaino AC, Walz A, Vermeer SJ, Barr J, Kovacs A, Fettig RR, et al. Functional neuronal circuits promote disease progression in cancer. Sci Adv. 2023;9:eade4443.
Google Scholar
Le TT, Payne SL, Buckwald MN, Hayes LA, Parker SR, Burge CB, et al. Sensory nerves enhance triple-negative breast cancer invasion and metastasis via the axon guidance molecule PlexinB3. NPJ Breast Cancer. 2022;8:116.
Google Scholar
Balood M, Ahmadi M, Eichwald T, Ahmadi A, Majdoubi A, Roversi K, et al. Nociceptor neurons affect cancer immunosurveillance. Nature. 2022;611:405–12.
Google Scholar
Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341:1236361.
Google Scholar
Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H. Nerve-cancer cell cross-talk: a novel promoter of tumor progression. Cancer Res. 2015;75:1777–81.
Google Scholar
Wang W, Li L, Chen N, Niu C, Li Z, Hu J, et al. Nerves in the tumor microenvironment: origin and effects. Front Cell Dev Biol. 2020;8:601738.
Google Scholar
Silverman DA, Martinez VK, Dougherty PM, Myers JN, Calin GA, Amit M. Cancer-associated neurogenesis and nerve-cancer cross-talk. Cancer Res. 2021;81:1431–40.
Google Scholar
Malekan M, Nezamabadi SS, Samami E, Mohebalizadeh M, Saghazadeh A, Rezaei N. BDNF and its signaling in cancer. J Cancer Res Clin Oncol. 2023;149:2621–36.
Google Scholar
Yu Q, Wang Y, Yi G, Yang W, Chen K, Tan X, et al. BDNF is a prognostic biomarker involved in immune infiltration of lung adenocarcinoma and is associated with brain metastasis. Immunology. 2023;168:320–30.
Google Scholar
Di Pompo G, Mitsiadis TA, Pagella P, Pasquarelli A, Bettini G, Sabattini S, et al. Mesenchymal stroma drives axonogenesis and nerve-induced aggressiveness in osteosarcoma. J Exp Clin Cancer Res. 2025;44:276.
Google Scholar
Batchelor PE, Porritt MJ, Martinello P, Parish CL, Liberatore GT, Donnan GA, et al. Macrophages and microglia produce local trophic gradients that stimulate axonal sprouting toward but not beyond the wound edge. Mol Cell Neurosci. 2002;21:436–53.
Google Scholar
Ashrafi M, Baguneid M, Bayat A. The role of neuromediators and innervation in cutaneous wound healing. Acta Derm Venereol. 2016;96:587–94.
Google Scholar
Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.
Google Scholar
Schmid S, Russell ZR, Yamashita AS, West ME, Parrish AG, Walker J, et al. ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models. Cell Rep. 2024;43:114829.
Google Scholar
Abusalamah H, Reel JM, Lupfer CR. Pyruvate affects inflammatory responses of macrophages during influenza A virus infection. Virus Res. 2020;286:198088.
Google Scholar
Attri KS, Mehla K, Singh PK. Evaluation of macrophage polarization in pancreatic cancer microenvironment under hypoxia. In: Huang LE, editor. Hypoxia: Methods and Protocols. New York: Springer New York; 2018. p. 265-76.
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509–W14.
Google Scholar
Cieśla S, Wichtowski M, Poźniak-Balicka R, Murawa D. The surgical anatomy of the mammary gland. Vascularisation, innervation, lymphatic drainage and the structure of the axillary fossa (part 2. Nowotw J Oncol. 2021;71:62–9.
Google Scholar
Burgi K, Cavalleri MT, Alves AS, Britto LR, Antunes VR, Michelini LC. Tyrosine hydroxylase immunoreactivity as indicator of sympathetic activity: simultaneous evaluation in different tissues of hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2011;300:R264–71.
Google Scholar
Benn SC, Costigan M, Tate S, Fitzgerald M, Woolf CJ. Developmental expression of the TTX-resistant voltage-gated sodium channels Nav1.8 (SNS) and Nav1.9 (SNS2) in primary sensory neurons. J Neurosci. 2001;21:6077–85.
Google Scholar
Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991;350:230–2.
Google Scholar
Acheson A, Conover JC, Fandl JP, DeChiara TM, Russell M, Thadani A, et al. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature. 1995;374:450–3.
Google Scholar
Cho WG, Valtschanoff JG. Vanilloid receptor TRPV1-positive sensory afferents in the mouse ankle and knee joints. Brain Res. 2008;1219:59–65.
Google Scholar
Ernsberger U. The role of GDNF family ligand signalling in the differentiation of sympathetic and dorsal root ganglion neurons. Cell Tissue Res. 2008;333:353–71.
Google Scholar
Li CL, Li KC, Wu D, Chen Y, Luo H, Zhao JR, et al. Somatosensory neuron types identified by high-coverage single-cell RNA-sequencing and functional heterogeneity. Cell Res. 2016;26:83–102.
Google Scholar
Brown DC. Resiniferatoxin: the evolution of the “Molecular Scalpel” for chronic pain relief. Pharmaceuticals. 2016;9:47–58.
Olah Z, Szabo T, Karai L, Hough C, Fields RD, Caudle RM, et al. Ligand-induced dynamic membrane changes and cell deletion conferred by vanilloid receptor 1. J Biol Chem. 2001;276:11021–30.
Google Scholar
Ma C, Teoh HK, Zhao Y, Wang Y, Zhao J, Liu Y, et al. Reprogramming the immunosuppressive breast cancer microenvironment: integrating cellular, metabolic, and stromal targets for rational immunotherapy. Front Immunol. 2026;17:1760782.
Google Scholar
Steenbrugge J, Vander Elst N, Demeyere K, De Wever O, Sanders NN, Van Den Broeck W, et al. Comparative profiling of metastatic 4T1- vs. non-metastatic Py230-based mammary tumors in an intraductal model for triple-negative breast cancer. Front Immunol. 2019;10:2928.
Google Scholar
Li H, Miao YQ, Suo LP, Wang X, Mao YQ, Zhang XH, et al. CD206 modulates the role of M2 macrophages in the origin of metastatic tumors. J Cancer. 2024;15:1462–86.
Google Scholar
Li W, Li Y, Jin X, Liao Q, Chen Z, Peng H, et al. CD38: a significant regulator of macrophage function. Front Oncol. 2022;12:775649.
Google Scholar
Kawamura N, Katsuura G, Yamada-Goto N, Nakama R, Kambe Y, Miyata A, et al. Brain fractalkine-CX3CR1 signalling is anti-obesity system as anorexigenic and anti-inflammatory actions in diet-induced obese mice. Sci Rep. 2022;12:12604.
Google Scholar
Wlodarczyk M, Nowicka G. DNA damage, obesity and obesity-related health complications: what are new data telling us? Curr Opin Clin Nutr Metab Care. 2024;27:325–30.
Google Scholar
Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727–40.
Google Scholar
Carron EC, Homra S, Rosenberg J, Coffelt SB, Kittrell F, Zhang Y, et al. Macrophages promote the progression of premalignant mammary lesions to invasive cancer. Oncotarget. 2017;8:50731–46.
Google Scholar
Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, et al. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res. 2011;17:1741–52.
Google Scholar
Contreras-Zárate MJ, Day NL, Ormond DR, Borges VF, Tobet S, Gril B, et al. Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases. Oncogene. 2019;38:4685–99.
Google Scholar
Liu L, Dana R, Yin J. Sensory neurons directly promote angiogenesis in response to inflammation via substance P signaling. FASEB J. 2020;34:6229–43.
Google Scholar
Lei M, Liu Q, Nie J, Huang R, Mei Y, Pan D, et al. Impact and mechanisms of action of BDNF on neurological disorders, cancer, and cardiovascular diseases. CNS Neurosci Ther. 2024;30:e70138.
Google Scholar
Ali SR, Jordan M, Nagarajan P, Amit M. Nerve density and neuronal biomarkers in cancer. Cancers. 2022;14:4817–32.
Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 2000;14:2919–37.
Google Scholar
Kermani P, Hempstead B. Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med. 2007;17:140–3.
Google Scholar
Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood. 2005;105:4429–36.
Google Scholar
Tsai YF, Tseng LM, Hsu CY, Yang MH, Chiu JH, Shyr YM. Brain-derived neurotrophic factor (BDNF) -TrKB signaling modulates cancer-endothelial cells interaction and affects the outcomes of triple-negative breast cancer. PLoS One. 2017;12:e0178173.
Google Scholar
Ji XC, Dang YY, Gao HY, Wang ZT, Gao M, Yang Y, et al. Local injection of Lenti-BDNF at the lesion site promotes m2 macrophage polarization and inhibits inflammatory response after spinal cord injury in mice. Cell Mol Neurobiol. 2015;35:881–90.
Google Scholar
Yap NY, Toh YL, Tan CJ, Acharya MM, Chan A. Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment. Cytokine. 2021;144:155556.
Google Scholar
Laetsch TW, Hong DS. Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer. Clin Cancer Res. 2021;27:4974–82.
Google Scholar
Moriwaki K, Ayani Y, Kuwabara H, Terada T, Kawata R, Asahi M. TRKB tyrosine kinase receptor is a potential therapeutic target for poorly differentiated oral squamous cell carcinoma. Oncotarget. 2018;9:25225–43.
Google Scholar
Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, et al. Discovery of entrectinib: A new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. J Med Chem. 2016;59:3392–408.
Google Scholar
Liu D, Offin M, Harnicar S, Li BT, Drilon A. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag. 2018;14:1247–52.
Google Scholar
Meng L, Liu B, Ji R, Jiang X, Yan X, Xin Y. Targeting the BDNF/TrkB pathway for the treatment of tumors. Oncol Lett. 2019;17:2031–9.
Google Scholar
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–47.
Google Scholar
Cazorla M, Jouvenceau A, Rose C, Guilloux JP, Pilon C, Dranovsky A, et al. Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS One. 2010;5:e9777.
Google Scholar
